Elevated serum KL-6 concentrations in patients with diabetes mellitus. 2002

Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
First Department of Medicine, School of Medicine, Hokkaido University, N-15, W-7, Kita-ku, Sapporo, Japan. toruchan@sapmed.ac.jp

To clarify the influence of blood glucose level or diabetes mellitus on serum KL-6, a mucin-like glycoprotein, concentrations, they were measured against 176 diabetic subjects, including receiving insulin (INS) group (n=54), oral antidiabetics (OAD) group (n=78), and diet and exercise (D&E) group (n=44). Serum KL-6 concentrations in the diabetic subjects were significantly greater than those in the normal healthy control subjects (643.0+/-32.7 U/ml, 206.5+/-6.1 U/ml, P<.0001, respectively), and those in the INS and OAD groups were significantly greater than those in the D&E group (708.2+/-66.9, 691.7+/-51.9, and 476.6+/-34.9 U/ml, P<.05, P<.05, respectively). Serum KL-6 concentrations did not correlate with urine KL-6 concentrations (n=73, r= -.044, P= .74). Immunohistochemical staining of the diabetic kidneys with a monoclonal antibody to KL-6 antigen showed positive immunoreactivity on Henle's loop, renal tubules, and epithelial cells in Bowman's space of sclerosing glomerulus. In conclusion, diabetes mellitus or complications of diabetes mellitus resulted in serum KL-6 elevation regardless of serum glucose level, but serum KL-6 concentrations were not influenced despite control of diabetes mellitus.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
December 2018, The British journal of dermatology,
Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
October 2000, Nephron,
Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
August 2000, Chest,
Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
February 2021, Cancers,
Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
August 2014, BMC pulmonary medicine,
Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
February 2002, European journal of clinical investigation,
Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
December 1991, Clinica chimica acta; international journal of clinical chemistry,
Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
September 2013, Clinica chimica acta; international journal of clinical chemistry,
Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
April 2024, Surgical case reports,
Toru Takahashi, and Kei Takamura, and Sinji Sakaue, and Jun Ishii, and Hiroshi Yokouchi, and Yasuyuki Nasuhara
January 2000, Dermatology (Basel, Switzerland),
Copied contents to your clipboard!